Severe immune-related adverse events (irAE) induced by nivolumab at our institution

Hasegawa, Y; Tsukuda, H; Ota, T; Miyatake, N; Matsui, K; Fukuoka, M

ANNALS OF ONCOLOGY, 2017; 28 ( ):